Publications, Presentations and Posters
| 14 – 16 Oktober 2021
EORTC CLTF – Cutaneous Lymphoma Task Force Meeting Marseille, France |
RESMAIN study – Evaluating resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary syndrome (SS)Poster Mode-of-action of HDAC inhibitor |
| 15 – 17 April 2021
10th World Congress of Melanoma and 17th EADO Congress Virtual |
Phase II trial evaluating Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary syndrome (SS) – RESMAIN study |
| 26 – 28 September 2019
EORTC Cutaneous Lymphoma Meeting 2019 Athens, Greece |
Resminostat increases NK cell-mediated lysis of malignant cells beneficially affecting the function of opsonizing antibodies
HDACi resminostat causes a sustained reduction of the pruritus mediator IL-31 in CTCL cells. Transcriptional impact of resminostat and other HDAC inhibitors on disease-related gene expression in CTCL |
| 13 – 16 November 2018
ENA 2018 Dublin, Ireland |
HDAC inhibition: transcriptional impact of resminostat on disease-related processes in CTCL |
| 27 – 29 September 2018
EORTC CLTF Meeting 2018 St. Gallen, Switzerland |
Resminostat affects transcriptional regulation of disease-related processes in CTCL |
| 13 – 15 September 2018
28. Deutscher Hautkrebskongress Stuttgart, Germany |
A multicentre, double blind, randomized, placebo controlled, Phase II trial to evaluate resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study |
| 10 September 2018 Investigational New Drugs |
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients
Won Young Tak, Baek-Yeol Ryoo, Ho Yeong Lim, Do-Young Kim, Takuji Okusaka, Masafumi Ikeda, Hisashi Hidaka, Jong-Eun Yeon, Eishiro Mizukoshi, Manabu Morimoto, Myung-Ah Lee, Kohichiroh Yasui, Yasunori Kawaguchi, Jeong Heo, Sojiro Morita, Tae-You Kim, Junji Furuse, Kazuhiro Katayama, Takeshi Aramaki, Rina Hara, Takuya Kimura, Osamu Nakamura, Masatoshi Kudo Investigational New Drugs, 10 September 2018, DOI: 10.1007/s10637-018-0658-x |
| 30 August 2018 Leukemia & Lymphoma |
Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study
Jan Walewski, Ewa Paszkiewicz-Kozik, Gabriela Borsaru, Andrzej Hellmann, Andrea Janikova, Agnieszka Warszewska, Anna Mais, Astrid Ammendola, Thomas Herz, Babett Krauss & Stefan W. Henning Leukemia & Lymphoma, 30 August 2018, DOI: 10.1080/10428194.2018.1492122 |
| 11 July 2018 Investigational New Drugs |
Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer
Masafumi Ikeda, Izumi Ohno, Hideki Ueno, Shuichi Mitsunaga, Yusuke Hashimoto, Takuji Okusaka, Shunsuke Kondo, Mitsuhito Sasaki, Yasunari Sakamoto, Hideaki Takahashi, Rina Hara, Shingo Kobayashi, Osamu Nakamura and Chigusa Morizane. Investigational New Drugs, 11 July 2018, DOI: 10.1007/s10637-018-0634-5 |
| 30 June – 03 July 2018 EACR 2018 Amsterdam, The Netherlands |
Epigenetic insights – Resminostat regulates targets associated with the pathogenesis of cutaneous T cell lymphoma (CTCL)
HDACi resminostat in combination with sorafenib reverses platelet-mediated pro-tumorigenic effects in hepatocellular carcinoma |
| 5 December 2017 Oncotarget |
Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis
Soukupova J, Bertran E, Peñuelas-Haro I, Urdiroz-Urricelqui U, Borgman M, Kohlhof H and Fabregat I. Oncotarget. 2017; 8:110367-110379, doi: 10.18632/oncotarget.22775 |
| 13 – 15 October 2017 EORTC CLTF Meeting | Cutaneous Lymphomas: Insights & Therapeutic Progress 2017 Meeting London, Vereinigtes Königreich |
Resminostat’s action in CTCL – hints from a genome-wide study
A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study
|
| 21 – 23 September 2017 27. Deutscher Hautkrebskongress, ADO-Jahrestagung Mainz, Germany |
A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study |
| 12 – 16 June 2017 16th Annual World Preclinical Congress Boston, USA |
Epigenetic priming with HDAC inhibitor resminostat sensitizes cancer to NK cell based immunotherapy |
| 3 – 6 May 2017 13th Congress of the European Association of Dermato Oncology (EADO) Athens, Greece |
A multicentre, double blind, randomized, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study |
| 6 – 7 March 2017 Epigenetics in Drug Discovery Cambridge, United Kingdom9 – 10 March 2017Clinical Epigenetics International Meeting (CLEPSO) Dusseldorf, Germany |
Resminostat – An epigenetic approach for CTCL Maintenance Treatment |
| 31 January 2017 International Journal of Cancer and Clinical Research |
Acetylation of α-tubulin by a Histone Deacetylase Inhibitor, Resminostat, Leads Synergistic Antitumor Effect with Docetaxel in Non-Small Cell Lung Cancer Models
Konishi H, Takagi A, Takahashi H, Ishii S, Inutake Y and Matsuzaki T. International Journal of Cancer and Clinical Research, January 31, 2017, DOI:10.23937/2378-3419/1410077 |
| 30 January 2017 Investigational New Drugs |
Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small celllung cancer in patients previously treated with platinum-based chemotherapy.
Tambo Y, Hosomi Y, Sakai H, Nogami N, Atagi S, Sasaki Y, Kato T, Takahashi T, Seto T, Maemondo M, Nokihara H, Koyama R, Nakagawa K, Kawaguchi T, Okamura Y, Nakamura O, Nishio M, Tamura T. Invest New Drugs. 2017 Jan 30. doi: 10.1007/s10637-017-0435-2. [Epub ahead of print] |
| 29 November – 2 December 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium Munich, Germany |
Biomarker summary analysis for the histone deacetylase inhibitor resminostat – Review and conclusions based on three oncology Phase I and Phase II trials
Resminostat, a new treatment option in cutaneous T cell lymphoma (CTCL) Resminostat, a Phase II clinical HDAC inhibitor, sensitizes tumor cells for NK cell response and synergizes with ADCC therapy |
| November 2016 International Journal of Oncology |
Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus.
Ellerhoff TP, Berchtold S, Venturelli S, Burkard M, Smirnow I, Wulff T, Lauer UM. Int J Oncol. 2016 Nov;49(5):1931-1944. doi: 10.3892/ijo.2016.3675. |
| 26 – 28 October 2016 3rd World Congress of Cutaneous Lymphomas New York, USA |
Resminostat – An epigenetic approach for CTCL Maintenance Treatment |
| August 2016 Journal of Hepatology |
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study.
Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B. J Hepatol. 2016 Aug;65(2):280-8. doi: 10.1016/j.jhep.2016.02.043. |
| 16 June 2016 World Preclinical Congress – Cancer Immonotherapy and Combinations Congress Boston, USA |
Epigenetic therapeutics for combination with cancer immunotherapy |
| 6 November 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference Boston, USA |
Immunomodulatory effects of the novel HDAC inhibitor resminostat |
| October 2015 Molecular Therapy Oncolytics |
Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.
Ruf B, Berchtold S, Venturelli S, Burkard M, Smirnow I, Prenzel T, Henning SW, Lauer UM. Mol Ther Oncolytics. 2015 Oct 7;2:15019. doi: 10.1038/mto.2015.19. |
| 23 July 2015 6th Annual EpiCongress Boston, USA |
Reprogramming cancer: 4SC-202 and resminostat are impacting tumor antigen presentation and overcoming immune tolerance |
| June 2015 Cancer Chemotherapy and Pharmacology |
A phase I study of resminostat in Japanese patients with advanced solid tumors.
Kitazono S, Fujiwara Y, Nakamichi S, Mizugaki H, Nokihara H, Yamamoto N, Yamada Y, Inukai E, Nakamura O, Tamura T. Cancer Chemother Pharmacol. 2015 Jun;75(6):1155-61. doi: 10.1007/s00280-015-2741-8. |
| 27 March 2015 ECCO ITOC Conference Munich, Germany |
Immunomodulatory characteristics of Resminostat, a novel HDAC inhibitor in phase II clinical development |
| 25 – 26 November 2014 4th Munich Biomarker Conference Munich, Germany |
ZFP64 – a predictive RNA biomarker for cancer treatment with the HDAC inhibitor Resminostat |
| October 2013 Clinical Cancer Research |
First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.
Brunetto AT, Ang JE, Lal R, Olmos D, Molife LR, Kristeleit R, Parker A, Casamayor I, Olaleye M, Mais A, Hauns B, Strobel V, Hentsch B, de Bono JS. Clin Cancer Res. 2013 Oct 1;19(19):5494-504. doi: 10.1158/1078-0432.CCR-13-0735. |
| 27 September – 1 October 2013 European Cancer Congress (ECCO 2013) Amsterdam, The Netherlands |
Subgroup analysis of prognostic factors for overall survival in the SHELTER trial evaluating resminostat in advanced hepatocellular carcinoma (HCC) |
| 13 – 15 September 2013 7th Annual Conference of the International Liver Cancer Association (ILCA) Washington, D.C., USA |
Resminostat In Advanced Hepatocellular Carcinoma (HCC): Overall Survival Subgroup Analysis Of Prognostic Factors In The Shelter Trial |
| 31 May – 4 June 2013 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago, USA |
Phase I dose escalation of the oral histone deacetylase inhibitor (HDACi) resminostat in combination with FOLFIRI in colorectal cancer (CRC) patients: the SHORE trial |
| 18 – 20 April 2013 3rd ITLT Essen 2013: Interdisciplinary Treatment of Liver Tumors Essen, Germany |
Pharmacokinetic characteristics of the new treatment combination of sorafenib and resminostat, a novel histone deacetylase (HDAC) inhibitor, in patients with advanced hepatocellular carcinoma (HCC): the SHELTER study |
| 8 – 9 November 2012 2nd Cancer Epigenetics Conference Boston, USA |
Resminostat: Targeting Drug Tolerance by Epigenetic Regulation of Histone Acetylation |
| 14 – 16 September 2012 ILCA Konferenz: 6. Jahrestagung der International Liver Cancer Association (ILCA) Berlin, Germany |
Efficacy, Tolerability and Pharmacokinetics of the Oral Histone Deacetylase Inhibitor Resminostat in Patients with Advanced Hepatocellular Carcinoma: Clinical Data from the Phase 2 Shelter Study |
| 27 – 30 June 2012 EMSO GI Konferenz: 14th World Congress on Gastrointestinal Cancer of the European Society for Medical Oncology Barcelona, Spain |
Dose Escalation of the HDAC Inhibitor Resminostat in Combination Treatment with Sorafenib in Patients with Hepatocellular Carcinoma – The Phase I/II SHELTER study |
| 14 – 17 June 2012 17th Congress of the European Hematology Association (EHA) Amsterdam, The Netherlands |
Efficient HDAC inhibition and TARC reduction in patients with refractory Hodgkin’s lymphoma treated with Resminostat. PK/PD data from the Phase II SAPHIRE study |
| 1 – 5 June 2012 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago, USA |
Efficacy, safety, tolerability and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study Press Release |
| 19 – 21 January 2012 2012 Gastrointestinal Cancer Symposium (ASCO, ASTRO, SSO) San Francisco, USA |
Investigation of the HDAC Inhibitor Resminostat in Patients with Sorafenib-Resistant Hepatocellular Carcinoma (HCC): Clinical Data from the Phase I/II SHELTER Study |
| 10 – 13 December 2011 ASH San Diego, USA |
Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma |
| 7 – 8 December 2011 2nd World Epigentic Summit Munich, Germany |
Resminostat: A Novel Oral Histone Deacetylase Inhibitor in Phase II Clinical Development |
| 22 – 25 June 2011 ESMO 13th World Congress on Gastrointestinal Cancer Barcelona, Spain |
Clinical Update of the SHELTER Study: A Phase I/II Trial of HDAC Inhibitor Resminostat in Patients with Sorafenib-Resistant Hepatocellular Carcinoma (HCC) PosterA Phase I/II Study of Resminostat, an Oral Histone Deacetylase Inhibitor (HDACi), in Combination with FOLFIRI as Second-Line Treatment in KRAS Mutated Colorectal Cancer (CRC) patients – the SHORE Study Poster |
| 20 – 21 January 2011 2011 Gastrointestinal Cancer Symposium (ASCO, ASTRO, SSO) San Francisco, USA |
Clinical Update of the SHELTER Study: A Phase I/II Trial of HDAC Inhibitor Resminostat in Patients with Sorafenib-Resistant Hepatocellular Carcinoma (HCC) |
| 4 – 7 December 2010 ASH Orlando, USA |
Resminostat in Relapsed or Refractory Hodgkin Lymphoma: Initial Results of the SAPHIRE Phase II Trial with a Novel Oral Histone Deacetylase (HDAC) inhibitor |
| 16 – 19 November 2010 22nd EORTC-NCI-AACR Symposium Berlin, Germany |
Centralised Analysis of Phase I ECG Dataset of Resminostat, a New Oral Histone Deacetylase Inhibitor (HDACi) |
| 23 – 26 October 2010 International Symposium on Hodgkin Lymphoma Cologne, Germany |
Initial Results from the SAPHIRE Study: A Phase II Trial with the Novel Oral Histone Deacetylase (HDAC) Inhibitor Resminostat in Relapsed or Refractory Hodgkin Lymphoma Patients |
| 17 September 2010 Viszeralmedizin 2010 Symposium Stuttgart, Germany |
First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC) – the SHELTER study |
| May 2010 British Journal of Haematology |
The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P. Br J Haematol. 2010 May;149(4):518-28. doi: 10.1111/j.1365-2141.2010.08124.x. |
| 29 May – 2 June 2009 ASCO Orlando, USA |
A first-in-human Phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with solid tumors |